If you have been told you need bladder removal surgery (radical cystectomy) for muscle-invasive bladder cancer, you may now be offered a new treatment called durvalumab.
Patients are searching:
- Does durvalumab improve survival in bladder cancer?
- What is the success rate?
- How many people benefit?
- Is it better than nivolumab?
- What are the risks?
- Is it available on the NHS?
What Is Muscle-Invasive Bladder Cancer and Why Is Recurrence Common?
Muscle-invasive bladder cancer (MIBC) means the tumour has grown into the muscle layer of the bladder wall.
This stage is serious because:
- Around 40–50% of patients develop recurrence or spread after surgery.
- Once the cancer spreads, long-term survival drops significantly.
Standard treatment has been:
- Chemotherapy (gemcitabine + cisplatin)
- Radical cystectomy
- Monitoring afterwards
Now, immunotherapy is added before and after surgery.
What Is Durvalumab, and How Does It Work?
Durvalumab is an immunotherapy drug.
Immunotherapy helps your immune system recognise and destroy cancerous cells.
Cancer cells hide using a protein called PD-L1.
Durvalumab blocks PD-L1 so your immune system can see the cancer.
In this treatment plan:
- Durvalumab is given with chemotherapy before surgery
- Surgery removes the bladder
- Durvalumab continues after surgery
This is called perioperative immunotherapy.
It has been approved by the National Institute for Health and Care Excellence for NHS use.
Does Durvalumab Reduce the Risk of Bladder Cancer Coming Back?
Yes. This is the strongest evidence.
The main study measured event-free survival (EFS).
What is Event-Free Survival?
It means:
- No cancer recurrence
- No spread
- No death
The Real 2-Year Results
At 2 years:
- 68 out of 100 patients who received durvalumab had no recurrence
- 60 out of 100 patients who had chemotherapy alone had no recurrence
Absolute improvement = 8%
That means:
8 extra patients per 100 avoid recurrence at 2 years.
Relative vs Absolute Risk: Why the Numbers Sound Different
The study reports a hazard ratio (HR) of 0.68.
This equals a:
32% relative reduction in risk of recurrence or death.
But this does NOT mean 32 out of 100 patients benefit.
It means the risk is reduced by one-third compared to chemotherapy alone.
The real-world difference is:
8 extra patients per 100 benefit at 2 years.
Relative numbers sound bigger.
Absolute numbers show the practical impact.
How Many Patients Need Treatment for One to Benefit? (NNT Explained)
The Number Needed to Treat (NNT) tells us how many people must receive treatment for one extra person to benefit.
Formula:
NNT = 1 ÷ Absolute Risk Reduction
NNT = 1 ÷ 0.08
NNT = 12.5
So:
13 patients need to be treated for 1 additional patient to avoid recurrence at 2 years.
In cancer treatment, an NNT of 13 is considered meaningful.
Does Durvalumab Improve Overall Survival?
T
he hazard ratio for death was approximately 0.75.
This means:
This indicates a 25% relative reduction in the risk of death when compared to chemotherapy alone.
However:
- Long-term survival data is still maturing.
- Median overall survival has not yet been reached.
- Final 5-year survival numbers are still evolving.
So the survival signal is promising but not yet definitive.
Does It Increase Complete Cancer Clearance at Surgery?
Yes.
The study measured pathological complete response (pCR).
This means no cancer is found when the bladder is removed.
Results:
- 37 out of 100 patients with durvalumab had complete response
- 27 out of 100 with chemotherapy alone had complete response
That is a 10% absolute improvement.
Complete response is strongly linked to better long-term outcomes.
What Are the Side Effects of Durvalumab?
All cancer treatments carry risks.
Severe Side Effects (Grade 3–4)
- 63–64% with durvalumab
- 52–55% with chemotherapy alone
This is about an 8–10% increase in severe side effects.
What Are Immune-Related Side Effects?
Because durvalumab activates the immune system, it can sometimes attack normal organs.
Serious immune-related problems occurred in about 6–8 out of 100 patients.
These may include:
- Thyroid damage (may require lifelong tablets)
- Bowel inflammation
- Lung inflammation
- Liver inflammation
- Pituitary gland problems
Most are manageable, but some can be permanent.
Putting the Numbers Together: Benefit vs Risk
If 100 patients receive durvalumab:
Benefits
- 8 extra avoid recurrence at 2 years
- 10 extra achieve complete tumour clearance
- Early survival improvement signal
Risks
- 8–10 extra experience severe side effects
- 6–8 develop serious immune complications
This is the honest trade-off.
Is Durvalumab Better Than Nivolumab?
Some patients previously received adjuvant nivolumab after surgery.
Differences:
- Nivolumab is given only after surgery
- Mainly used in PD-L1 positive tumours
- Durvalumab is given before and after surgery
- No direct comparison trial exists
The National Institute for Health and Care Excellence reviewed the modelling data and approved durvalumab as cost-effective.
Who Is the Best Candidate for Durvalumab?
The trial average age was mid-60s.
In the UK:
- Many patients are older (70+)
- Older patients may have heart or lung disease
- Fitness for cisplatin chemotherapy remains essential
This treatment is mainly for:
- Fit patients
- Cisplatin-eligible patients
- Those able to tolerate immunotherapy
Frequently Asked Questions
Does durvalumab improve survival in bladder cancer?
Yes. It reduces the recurrence risk by 32% and shows a 25% relative reduction in death risk, although long-term survival data is still maturing.
What is the success rate of durvalumab in bladder cancer?
At 2 years, 68% of patients remained recurrence-free compared to 60% with chemotherapy alone.
How many people benefit from durvalumab?
About 1 in 13 treated patients gains additional protection against recurrence at 2 years.
Is durvalumab available on the NHS?
Yes. It has been approved by NICE for routine use in eligible patients.
What are the most serious side effects?
Around 6–8% develop serious immune-related complications. Severe side effects overall increase by about 8–10%.
Is Durvalumab Worth It?
Durvalumab offers:
- 8% absolute reduction in recurrence at 2 years
- 32% relative reduction in recurrence risk
- NNT of 13
- 10% increase in complete tumour clearance
- Around 10% increase in severe toxicity
For fit patients with muscle-invasive bladder cancer, this represents a meaningful advance.
For older or frail patients, individualised discussion is essential.
As longer-term data emerges, we will better define the true survival impact.
